Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.53 |
| ▸ | NT5E | P21589 | 10/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.46 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22700147 | 1.00 | PDE2A (0.53) | PDE2ANT5EADORA2AADORA3P2RY1 | |
| SCHEMBL19974411 | 0.89 | PDE2A (0.46) | PDE2ANT5EADORA2AADORA3 | |
| SCHEMBL22700164 | 0.87 | PDE2A (0.52) | PDE2ANT5EADORA3P2RY1P2RY11 | |
| SCHEMBL19979029 | 0.87 | ADORA2A (0.57) | NT5EADORA2AADORA3P2RY1P2RY11 | |
| SCHEMBL19974418 | 0.87 | ADORA2A (0.57) | NT5EADORA2AADORA3P2RY1P2RY11 | |
| SCHEMBL19974427 | 0.86 | ADORA2A (0.68) | PDE2ANT5EADORA2AADORA3 | |
| SCHEMBL19975000 | 0.80 | ADORA2A (0.58) | NT5EADORA2AADORA3P2RY1P2RY11 | |
| SCHEMBL22700162 | 0.79 | PDE2A (0.46) | PDE2ANT5EADORA3 | |
| SCHEMBL19974603 | 0.78 | NT5E (0.44) | NT5EADORA2AADORA3P2RY1P2RY11 | |
| SCHEMBL19974435 | 0.78 | ADORA2A (0.49) | NT5EADORA2AADORA3P2RY1P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434255-B2 | Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent | LCB PHARMA INC. (CA) | 2022-09-06 | — | — | US | disclosed |
| EP-3512860-B1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC (CA) | 2020-11-25 | — | — | EP | disclosed |
| EP-3512860-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB Pharma Inc. (CA) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018049534-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434255-B2 | Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent | TNNT2, NT5C2, PNP | PDE2A 742/4885NT5E 20/4885ADORA2A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.